NCT02649725

Brief Summary

The purpose of this study is to determine whether there is positive (beneficial) impact of expensive cytotoxic agents on the cancer patients. It is a questionnaire based study that will be filled by the cancer patients without obligations.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,800

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2016

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2016

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

January 6, 2016

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 7, 2016

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2018

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2019

Completed
Last Updated

May 3, 2016

Status Verified

May 1, 2016

Enrollment Period

2.8 years

First QC Date

January 6, 2016

Last Update Submit

May 1, 2016

Conditions

Patient's Satisfaction

Outcome Measures

Primary Outcomes (1)

  • The patient's satisfaction questionnaire

    Two years

Interventions

patient's satisfactionBEHAVIORAL

Questionnaire based measurement.

Eligibility Criteria

Age17 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Cancer patients who are willing to answer the questionnaire voluntarily.

You may qualify if:

  • The patient should be willing to share in the study.
  • The patient should have full mental power to answer the questionnaire.
  • Adult from 17 to 70 years.
  • Patient should be able to complete the course of treatment without interruption due to financial issues or other issues like transportation obstacles.

You may not qualify if:

  • The patient with psychological disease that impairs credibility of his answer.
  • Patient with special requirements/difficulties with communications.
  • Patient who have difficulty with their memory e.g. recall of events, learning new things, remembering appointments.
  • Patient who have epilepsy blackouts or dizzy spills.
  • Patient who have any visual impairment other than standard glasses.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Medicine. AIn Shams University

Cairo, Elabbasia, Egypt

RECRUITING

Study Officials

  • Noha S Elbaghdady, Specialis

    Misr University for Science and Technology

    STUDY DIRECTOR

Central Study Contacts

Mahmoud A Ellithy, Consultant

CONTACT

01000069694ellithym@med.asu.edu.eg

Lamiaa Elwakil, Consultannt

CONTACT

01005201099lamywak@yahoo.com

Study Design

Study Type
observational
Observational Model
ECOLOGIC OR COMMUNITY
Time Perspective
PROSPECTIVE
Target Duration
3 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate professor of clinical oncology.Faculty of Medicine.

Study Record Dates

First Submitted

January 6, 2016

First Posted

January 7, 2016

Study Start

January 1, 2016

Primary Completion

November 1, 2018

Study Completion

January 1, 2019

Last Updated

May 3, 2016

Record last verified: 2016-05

Data Sharing

IPD Sharing
Will not share

Locations

EG(1)